Rosetta Genomics has announced that the NASDAQ Listing Qualifications Staff has determined that the Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market® as set forth in NASDAQ Listing Rule 5550(b)(1).
NASDAQ will continue to monitor the Company's periodic reports to confirm the Company's ongoing compliance with the stockholders' equity requirement.
"As a result of our recently announced registered direct offerings, we were successful in increasing stockholders' equity beyond NASDAQ's listing requirement. We are very pleased to have regained compliance with the rule," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
Berlin continued, "With this determination by NASDAQ, we are now in compliance with the continued listing requirements of The NASDAQ Capital Market."